Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BD 111

Next Previous
X
Search
Drug Profile

BD 111

Alternative Names: BD-111; CRISPER/Cas9 mRNA instantaneous gene editing therapy; HSV-1-erasing lentiviral particles - BDgene Therapeutics

Latest Information Update: 03 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai BDgene
  • Class Antivirals; Eye disorder therapies; Gene therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Dendritic keratitis

Most Recent Events

  • 25 Jun 2024 Shanghai BDgene plans phase-IIa trial for Ocular herpes simplex (Combination therapy, In adults, In the elderly) in China (Intraocular, injection) in September 2024 (NCT06474442),
  • 04 Sep 2023 Shanghai BDgene initiates a phase I trial in Dendritic keratitis (Treatment-experienced) in China (Intraocular) (NCT06474416)
  • 05 Jul 2022 Shanghai BDgene completes a Phase-I/II clinical trials in Dendritic keratitis (Treatment-experienced) in China (Intraocular) (NCT04560790)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top